Delcath Systems, Inc.
NASDAQ•DCTH
CEO: Mr. Gerard J. Michel MBA, MS
セクター: Healthcare
業種: Medical - Devices
上場日: 2018-05-03
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
連絡先情報
時価総額
$328.35M
PER (TTM)
127.6
26.6
配当利回り
--
52週高値
$18.23
52週安値
$8.12
52週レンジ
順位54Top 78.1%
2.7
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
弱い • 2.7 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025
財務ダッシュボード
Q4 2025 データ
売上高
$20.73M+0.00%
直近4四半期の推移
EPS
-$0.05+0.00%
直近4四半期の推移
フリーCF
$7.70M+0.00%
直近4四半期の推移
2025 Annual 決算ハイライト
主なハイライト
Revenue Surges 129% Total revenues reached $85.23M in 2025, marking a 129.1% increase from $37.21M in 2024.
Achieved Net Income Switched to $2.7M net income in 2025, reversing prior year's $26.4M net loss.
CHOPIN Trial Positive Results CHOPIN Phase 2 trial met PFS endpoint; combination group PFS 12.8 months versus 8.3 months.
Cash Position Strengthened Cash and equivalents grew to $43.5M by year-end 2025, supported by $22.5M net cash from operations.
リスク要因
Capital Resources Exhaustion Risk Continuing losses may exhaust capital resources; success depends on generating substantial revenue from HEPZATO sales.
Supply Chain Component Reliance Must maintain supply agreements for melphalan; reliance on single supplier increases risk of commercialization impairment.
Regulatory Approval Uncertainty Future product development, including clinical trials for new indications, depends on obtaining necessary regulatory approvals.
Stock Volatility and Dilution Common stock price remains volatile; future equity issuances pursuant to outstanding warrants may cause substantial dilution.
見通し
Expand Clinical Development Plan to generate clinical data for CHEMOSAT/HEPZATO in broader liver cancer indications, including mCRC and mBC trials.
Support Product Adoption Expect publications to support increased clinical adoption and reimbursement for CHEMOSAT across various jurisdictions.
Manage Capital Requirements Liquidity sufficient for 12 months; future capital needs depend on clinical trial progress and regulatory approvals.
Continue Share Repurchase Board authorized $25M repurchase program; $19.0M remained available for use as of December 31, 2025.
同業比較
売上高 (TTM)
$5.93B
$568.09M
$329.52M
粗利益率 (最新四半期)
91.5%
85.5%
80.6%
主要指標
銘柄コード | 時価総額 | PER (TTM) | ROE (TTM) | 負債比率 |
|---|---|---|---|---|
| SRDX | $614.51M | -34.8 | -15.6% | 19.2% |
| TCMD | $604.28M | 31.6 | 9.3% | 5.8% |
| BVS | $577.34M | 25.3 | 13.8% | 45.5% |
長期トレンド
直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
1.6%
緩やかな成長
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
100%
優れたキャッシュフローの実績
深度リサーチ
次回決算:2026年5月6日
EPS:-
|売上高:-
財務データ
決算説明会
財務レポート
ニュース
損益計算書
バランスシート
キャッシュフロー計算書
財務比率
変化率
損益計算書 | 直近12ヶ月 |
|---|
データなし